Adaptive Biotechnologies articles
This September marks four years since the 2018 Food and Drug Administration clearance for clonoSEQ to detect and monitor minimal residual disease (MRD) in bone marrow from patients with acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). In the years following, researchers have explored the value of using MRD status to guide treatment in blood cancers – and the mounting evi
"If it makes sense to you it doesn’t have to make sense to anyone else. Follow your passion."
Here at Adaptive we understand that fostering an empowering environment for future STEM leaders through rich mentoring opportunities will be key to enabling them to find their own professional paths later in life.
In March, Adaptive hosted a Field Day for you
Here at Adaptive, putting the patient first is a core value—a philosophy that deeply resonates with me. Similar to many of my fellow Adapters, my inspiration is personal and I’m excited by the tremendous potential impact we can have on human lives through the work we’re doing in our Immune Medicine and MRD businesses.
Growing up in New Delhi, India, my father work
As September and Blood Cancer Awareness Month wrap up, we want to reflect on a memorable conversation with Karen Thomas, a woman who received clonoSEQ® testing, and her physician, Dr. Hazma Hashmi, a hematologist-oncologist from the Medical University of South Carolina. At Adaptive, we know our diagnostic tests provide key information that help physicians and patients make treatment de
In honor of World Cancer Day, we sat down with two Adapters to understand how their personal experiences with cancer intersect with their work at Adaptive. Kathy Thompson (Key Account Manager, clonoSEQ sales) is a stage 1 colorectal cancer survivor. Shannon Fatigante (Talent Acquisition Senior Program Manager) has a father currently fighting chronic lymphocytic leukemia